Effect of dutasteride on the risk of prostate cancer
| Autor: | Andriole, G.L., Bostwick, D.G., Brawley, O.W., Gomella, L.G., Marberger, M., Montorsi, F., Pettaway, C.A., Tammela, T.L.J., Teloken, C., Tindall, D.J., Somerville, M.C., Wilson, T.H., Fowler, I.L., Rittmaster, R.S., Mulders, P.F.A., Schrier, B.P. |
|---|---|
| Přispěvatelé: | Department of urology, Università Vita-Salute San Raffaele, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Andriole Gerald, L., Bostwick David, G., Brawley Otis, W., Gomella Leonard, G., Marberger, Michael, Montorsi, Francesco, Pettaway Curtis, A., Tammela Teuvo, L., Teloken, Claudio, Tindall Donald, J., Somerville Matthew, C., Wilson Timothy, H., Fowler Ivy, L., Rittmaster Roger, S., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques |
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
Relative risk reduction Prostate biopsy Biopsy MESH : Risk Prostatic Hyperplasia 030232 urology & nephrology MESH : Aged MESH: Protein Isoforms [ SDV.CAN ] Life Sciences [q-bio]/Cancer MESH: Biopsy chemistry.chemical_compound Prostate cancer 5-alpha Reductase Inhibitors 0302 clinical medicine Erectile Dysfunction Protein Isoforms MESH: Double-Blind Method Enzyme Inhibitors MESH : Prostate-Specific Antigen 10. No inequality MESH: Treatment Outcome MESH: Erectile Dysfunction MESH: Aged MESH: Risk MESH: Middle Aged medicine.diagnostic_test Prostate General Medicine Middle Aged MESH : Prostatic Hyperplasia MESH: Prostate-Specific Antigen 3. Good health Prostate-specific antigen Treatment Outcome MESH: Enzyme Inhibitors 030220 oncology & carcinogenesis Finasteride medicine.symptom MESH : Prostatic Neoplasms Risk medicine.medical_specialty MESH : Male Urology [SDV.CAN]Life Sciences [q-bio]/Cancer MESH : Testosterone 5-alpha-Reductase MESH : Treatment Outcome MESH: Prostate MESH: Azasteroids MESH: Prostatic Hyperplasia 03 medical and health sciences Double-Blind Method Translational research [ONCOL 3] medicine Humans MESH : Double-Blind Method MESH : Middle Aged MESH: Testosterone 5-alpha-Reductase Aged MESH : Azasteroids Heart Failure Gynecology MESH : Enzyme Inhibitors MESH: Humans MESH : Erectile Dysfunction business.industry Urinary retention MESH : Humans Prostatic Neoplasms MESH : Protein Isoforms Dutasteride Prostate-Specific Antigen medicine.disease MESH: Male chemistry Azasteroids MESH: Prostatic Neoplasms MESH : Biopsy MESH: Heart Failure Prostate surgery business MESH : Heart Failure MESH : Prostate |
| Zdroj: | New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2010, 362 (13), pp.1192-1202. 〈10.1056/NEJMoa0908127〉 The New England Journal of Medicine, 362, 13, pp. 1192-202 The New England Journal of Medicine, 362, 1192-202 New England Journal of Medicine, Massachusetts Medical Society, 2010, 362 (13), pp.1192-1202. ⟨10.1056/NEJMoa0908127⟩ |
| ISSN: | 0028-4793 1533-4406 |
| Popis: | Background: We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Methods: In this 4-year, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, we compared dutasteride, at a dose of 0.5 mg daily, with placebo. Men were eligible for inclusion in the study if they were 50 to 75 years of age, had a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng per milliliter, and had had one negative prostate biopsy (6 to 12 cores) within 6 months before enrollment. Subjects underwent a 10-core transrectal ultrasound-guided biopsy at 2 and 4 years. Results: Among 6729 men who underwent a biopsy or prostate surgery, cancer was detected in 659 of the 3305 men in the dutasteride group, as compared with 858 of the 3424 men in the placebo group, representing a relative risk reduction with dutasteride of 22.8% (95% confidence interval, 15.2 to 29.8) over the 4-year study period (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|